Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

Citations Over TimeTop 10% of 2009 papers

Abstract

All five technologies when added to supportive treatment and used at licensed dose(s) were more effective than supportive treatment alone in RCTs that included patients of mixed FC and types of PAH. Current evidence does not allow adequate comparisons between the technologies nor for the use of combinations of the technologies. Independent economic evaluation suggests that bosentan, sitaxentan and sildenafil may be cost-effective by standard thresholds and that iloprost and epoprostenol may not. If confirmed, the use of the most cost-effective treatment would result in a reduction in costs for the NHS. Long-term, double-blind RCTs of sufficient sample size that directly compare bosentan, sitaxentan and sildenafil, and evaluate outcomes including survival, quality of life, maintenance on treatment and impact on the use of resources for NHS and personal social services are needed.

Related Papers

• → Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects(2008)116 cited
• Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.(2006)
• → Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan(2009)14 cited
• → Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller(2007)7 cited
• → PHARMACOKINETIC INTERACTION BETWEEN TADALAFIL AND BOSENTAN IN HEALTHY MALE SUBJECTS(2006)6 cited